Clinical trials: Contrast Media
CT Scanning Patients
Observational Study to Assess the Safety of Omnipure® Inj.(Iohexol) Contrast Media in CT Scanning Patients
The purpose of this study is to assess safety of Omnipure inj. (lohexol) contrast media in CT scanning patients
- Trial name
- NCT02946450
- Testing
- Other: Not applicable-observational study
- Where
- South Korea
- Volunteers
- 3,000 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Rheumatoid Arthritis
To Estimate the Efficacy of Treatment With TNFi as Monotherapy or Combination Therapy With MTX and Compare and Contrast Efficacy With Tofacitinib as Monotherapy and Combination Therapy in a Real World Setting.
To estimate the efficacy of treatment with TNFi as monotherapy or combination therapy with MTX and compare and contrast efficacy with Tofacitinib as monotherapy and combination therapy in a real world setting.
- Trial name
- NCT05576051
- Testing
- patterns of use of combination therapy and monotherapy
- Where
- United States
- Volunteers
- 9,159 people
- Sponsor
- Pfizer
GI Carcinoma, GI Disorders
Phase 2 Study of NX9 for Delineation of Bowel Anatomy
This study will evaluate marking and distention of the bowel of the oral contrast agent, NX9, at CT of the abdomen and pelvis, VLDCT with no contrast will be followed by VLDCT with NX9 contrast followed by CT with NX9 and…
- Trial name
- NCT04789200
- Testing
- NX9 Oral Contrast Agent
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Nextrast, Inc.
Contrast Medium
Study on the Risk of Allergy-like Reactions After Intra-arterial or Intra-venous Injection of the Marketed X-ray Contrast Medium Iopromid
Iopromide (trade name is Ultravist) is on the market for more than 30 years and has been used more than 250 million times as X-ray contrast medium for patients.
- Trial name
- UVIA (NCT03622801)
- Testing
- Iopromide (Ultravist, BAY86-4877)
- Where
- Germany
- Volunteers
- 133,331 people
- Sponsor
- Bayer
Healthy Volunteer Study
Safety Study of CZ10 in Healthy Volunteers
A randomized, double-blind, placebo-controlled, parallel group, dose escalation study in healthy subjects to evaluate the safety, tolerability, pharmacokinetics and initial effectiveness of a novel intravenous CT contrast…
- Trial name
- NCT06708767
- Testing
- Contrast Media
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Nextrast, Inc.
Congestive Heart Failure, Chronic Obstructive Pulmonary Disease
Phase 1 Safety and Pharmacokinetic Study of AI-700 in Patients With Diminished DLCO and COPD and/or CHF
This study was conducted to evaluate the safety and pharmacokinetics of an echocardiographic contrast agent, AI-700, in patients with moderate to severe chronic obstructive pulmonary disease (COPD) and/or congestive heart failure…
- Trial name
- NCT00156780
- Testing
- AI-700
- Where
- United States
- Sponsor
- Acusphere
Coronary Artery Disease
Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart
CT (computed tomography) angiography (CTA) is an examination similar to a CAT scan that uses x-rays and a contrast medium (also called dye) to visualize blood flow in arteries and veins throughout the body VISIPAQUE™ will be…
- Trial name
- NCT00348608
- Testing
- iodixanol
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- GE Healthcare
Alzheimer Disease
Blood-Brain-Barrier Opening Using Focused Ultrasound With IV Contrast Agents in Patients With Early Alzheimer's Disease
This is a prospective, non-randomized, single-arm, feasibility study to evaluate the safety and initial effectiveness of opening of the Blood-Brain Barrier with intravenous contrast agents using the ExAblate Neuro System in…
- Trial name
- BBB-Alzheimers (NCT02986932)
- Testing
- BBB opening
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- InSightec
Colorectal Neoplasms, Neoplasm Metastasis
Health Economic Evaluation of Primovist-enhanced Liver MRI
Patients with a history of colorectal cancer and known or suspected liver metastases who are scheduled for contrast-enhanced tomographic imaging will be included in this study.
- Trial name
- NCT00764621
- Testing
- Primovist MRI, Extracellular contrast media (ECCM) MRI, Contrast-enhanced CT
- Where
- 44 sites in Austria, Germany and 7 more
- Volunteers
- 360 people
- Sponsor
- Bayer
Vascular Diseases
Evaluation of All'InCath in Peripheral Vasculature Percutaneous Transluminal Angioplasty.
The objective of this post-market clinical study is to obtain additional data on the safety and performance of the All'InCath 035M Balloon Dilatation Catheter when used per its Instructions for Use (IFU) during percutaneous…
- Trial name
- NCT05497440
- Testing
- All'InCath CBC 035M Balloon Dilatation Catheter
- Where
- United States
- Sponsor
- NexStep Medical
Breast Cancer, Breast Diseases
Contrast-Free Magnetic Resonance Imaging for Breast Disease
Prospective, observational cohort study looking at patients either at risk of breast cancer or have clinically suspected breast to assess the diagnostic performance of quantitative, non-contrast MRI.
- Trial name
- IMOGEN (NCT05006196)
- Testing
- Outpatient MRI
- Where
- United Kingdom
- Volunteers
- 1,030 people, healthy volunteers welcome
- Sponsor
- Perspectum
Contrast Enhancement in Magnetic Resonance Imaging
A Study Called GUS to Understand How Much of the Contrast Agent Gadavist is Used and How Much is Wasted in Two Different Containers (Single-dose Vials and Imaging Bulk Packages ) in a Real-world Setting
This is an observational study, in which data associated with the wastage with the use of Gadavist single-dose vials, as compared to the wastage associated with the use of the Gadavist imaging bulk packages (IBP) used for…
- Trial name
- NCT05350189
- Testing
- Gadobutrol (Gadavist/Gadovist, BAY86-4875)
- Where
- 2 sites in United States
- Volunteers
- 1,602 people
- Sponsor
- Bayer
Known or Highly Suspected Central Nervous System (CNS) Lesion, Known or Highly Suspected Body (Excluding CNS) Lesion
A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients
This is an operationally combined Phase 2/3 study, which will be conducted and evaluated in 2 distinct parts: Phase 2: Prospective, adaptive, multicenter, non-randomized, single-blind, dose-finding, including participants with…
- Trial name
- LUMINA (NCT07472491)
- Testing
- Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL, MRI Scan, Gadobutrol
- Where
- 7 sites in United States, Georgia and 2 more
- Volunteers
- 640 people
- Sponsor
- GE Healthcare
Relapsing Remitting Multiple Sclerosis, Optic Neuropathy
Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis
The objective of this trial is to assess the efficacy and safety of CNM-Au8 as a remyelinating treatment for vision-impairing MS lesions in participants who have chronic vision impairment as a result of Relapsing-Remitting…
- Conditions
- Relapsing Remitting Multiple Sclerosis, Optic Neuropathy, Optic; Neuritis, With Demyelination
- Trial name
- VISIONARY-MS (NCT03536559)
- Testing
- CNM-Au8
- Where
- 7 sites in United States, Australia and 1 more
- Volunteers
- 73 people
- Sponsor
- Clene Nanomedicine
Hyperopic Presbyopia
Prospective Investigation of SUPRACOR Visual Outcomes of Presbyopic Hyperopic Patients With and Without Astigmatism
This phase IV study is an open, prospective, single-center, single-surgeon bilateral eye study to investigate the bilateral uncorrected intermediate visual acuity of presbyopic hyperopic patients, who have been treated with…
- Trial name
- NCT01628146
- Testing
- SUPRACOR LASIK treatment
- Where
- Ireland
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Technolas Perfect Vision GmbH
Prostate Cancer
SonoVue Guided Prostate Biopsy
This is a phase III European multicenter, open label, prospective study to assess the diagnostic accuracy of the use of SonoVue contrast agent to guide prostate biopsies in comparison with the current practice of ultrasound…
- Trial name
- NCT00911027
- Testing
- Contrast-enhanced ultrasound guided biopsy, ultrasound guided systematic biopsy
- Where
- 17 sites in Austria, Belgium and 5 more
- Volunteers
- 282 people
- Sponsor
- Bracco Diagnostics, Inc
Focal Liver Lesions
Phase 4 Paediatric Study to Evaluate Sonazoid Safety and Efficacy for Contrast-Enhanced Ultrasound Liver Imaging
Liver tumours, 40% of which are benign, account for 1% to 4% of all solid tumours in children. The benign tumours are mainly haemangiomas, liver hamartomas, and liver cell adenomas.
- Trial name
- NCT06639828
- Testing
- Contrast-Enhanced Ultrasound
- Where
- 6 sites in Germany, Italy and 1 more
- Volunteers
- 50 people
- Sponsor
- GE Healthcare
Cardiac Disease
A Dose Ascending Study to Evaluate the Safety of NH002 as a Contrast Agent in Cardiac Echocardiography
NH002 (Perflutren Lipid Microspheres) Injectable Suspension is an ultrasound contrast agent for use in patients with suboptimal echocardiograms to opacify the left ventricular (LV) chamber and to improve the delineation of the LV…
- Trial name
- NCT04185246
- Testing
- NH002 (Perflutren Lipid Microspheres) Injectable Suspension, Echocardiogram
- Where
- 2 sites in Taiwan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Trust Bio-sonics, Inc.
Patients With Intraosseous Vascular Access Requiring Computed Tomography (CT) Exam
Observational Study of CT Dye Administration Through the Intraosseous Vascular Access Route
An observational study to determine the safety and effectiveness of Intraosseous (IO) vascular access for delivery of contrast dye for Computed Tomography (CT) examination.
- Trial name
- NCT01531686
- Testing
- Intraosseous delivery of CT contrast dye
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Vidacare Corporation
Thrombosis, Venous
The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients
The primary objective of this study is to evaluate the efficacy (as measured by the rate of recurrent symptomatic Venous Thromboembolism [VTE] (i.e., Pulmonary thromboembolism [PE] and Deep Vein Thrombosis [DVT])) and safety of…
- Trial name
- NCT00911157
- Testing
- Fondaparinux sodium, unfractionated heparin (UFH)
- Where
- 24 sites in Japan
- Volunteers
- 39 people
- Sponsor
- GlaxoSmithKline